CDR 505
Alternative Names: CDR-505Latest Information Update: 03 Mar 2023
At a glance
- Originator CDR-Life
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 30 Jan 2023 Early research in Solid tumours in Switzerland (Parenteral) (CDR-Life pipeline, January 2023)